Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe.

Diana Gosálvez Prados — última modificación 6/10/2014 10:25

Descripción:
Combined oral anticoagulant (OAC) and antiplatelet (AP) therapy is generally discouraged in atrial fibrillation (AF) outside of acute coronary syndromes or stenting because of increased bleeding. We evaluated its frequency and possible reasons in a contemporary European AF population.

Como citar:

De Caterina R et al. Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. Heart. 2014 Oct 15;100(20):1625-35. Available at: http://heart.bmj.com/content/100/20/1625.long

Tipo de documento:
Artículo

Fecha de creación:
6/10/2014

None

Autores:
De Caterina R et al.

Área geográfica:
Europa